We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





PHASE Scientific Launches RNA Extraction Kit for COVID-19 Test

By LabMedica International staff writers
Posted on 10 Apr 2020
Print article
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
PHASE Scientific (Hong Kong) has commercially launched the PHASIFY VIRAL RNA Extraction Kit as part of its global effort to help detect and control the COVID-19 disease. PHASIFY VIRAL purifies and concentrates viral RNA in patient viral transport media samples. This novel technology outperforms conventional solid phase extraction methods in RNA yield and concentration.

PHASE Scientific is a biotech company which builds tools that empower people by giving them better information about their health. The PHASIFY VIRAL kit, which incorporates the PHASIFY proprietary liquid phase extraction technology, produces greater viral RNA yields. This is enabled by an increased sample input volume up to 1 mL per extraction, and enhanced final viral RNA concentration with flexible elution volume down to 10 µL. The kit’s easy-to-use design requires no additional specialized equipment, such as magnetic racks and vacuum pumps, for operation.

PHASIFY concentrates target molecules by 10-100x, making them easier to detect. PHASIFY can make any diagnostic test more affordable, faster, easier, and more accurate. As proven by validation data, the PHASIFY VIRAL RNA extraction kit enables a 3-6 cycle threshold reduction compared to solid phase extraction. The applications of the PHASIFY VIRAL RNA Extraction Kit can be expanded to cover a wide scope of RNA-type virus extractions to help research institutes, hospitals, and diagnostic labs to improve diagnostic performance.

“We believe the PHASIFY VIRAL kit will be a new breakthrough approach for the fight against the COVID-19 disease. Our products can help increase detection sensitivity, decrease false negative results, enable earlier detection and increase confidence in diagnostic test results,” said Ricky Chiu, Ph.D., Founder and CEO of PHASE Scientific.

Related Links:
PHASE Scientific

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.